Filing Details
- Accession Number:
- 0001209191-17-015523
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-02-28 19:36:00
- Reporting Period:
- 2017-02-27
- Filing Date:
- 2017-02-28
- Accepted Time:
- 2017-02-28 19:36:00
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1513818 | Versartis Inc. | VSAR | Pharmaceutical Preparations (2834) | 264106690 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1601949 | Paul Westberg | C/O Versartis, Inc. 4200 Bohannon Drive, Suite 250 Menlo Park CA 94025 | Svp And Chief Business Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2017-02-27 | 7,509 | $1.61 | 77,053 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2017-02-27 | 4,991 | $2.53 | 82,044 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2017-02-27 | 12,500 | $22.50 | 69,544 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2017-02-27 | 7,509 | $0.00 | 7,509 | $1.61 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2017-02-27 | 4,991 | $0.00 | 4,991 | $2.53 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 2,975 | 2023-07-14 | No | 4 | M | Direct | |
| 7,491 | 2023-12-04 | No | 4 | M | Direct |
Footnotes
- Shares sold pursuant to a 10b5-1 trading plan.
- Twenty-Five percent of the shares subject to the option become exercisable one year from 7/15/2013; the remainder become exercisable in equal monthly installments over the following three years.
- Twenty-Five percent of the shares subject to the option become exercisable one year from 12/5/2013; the remainder become exercisable in equal monthly installments over the following three years.
Billionaire Hedge Funds
